Meddenovo Drug Design develops AI-supported solutions to design cyclic peptide therapeutics.
Meddenovo Drug Design's investors include ACT Venture Partners, Invest 101.
Meddenovo Drug Design is headquartered in Lyon, France.
Meddenovo Drug Design develops AI-supported solutions to design cyclic peptide therapeutics.
Meddenovo Drug Design is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Meddenovo Drug Design — Funding & Investors." VCBacked, January 1, 2025, https://www.vcbacked.co/company/meddenovo-drug-design. Accessed August 14, 2026.
VCBacked. (2025). Meddenovo Drug Design — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/meddenovo-drug-design
{{cite web |title=Meddenovo Drug Design — Funding & Investors |url=https://www.vcbacked.co/company/meddenovo-drug-design |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated